

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

### Complete if Known

Application Number	09/993,647
Filing Date	11/27/01
First Named Inventor	RIEDL
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	BAYER-18A

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
DR	AA	502,504	U.S.	Thoms	08-01-1883	
DR	AF	2,649,476	U.S.	Martin	08-15-1953	
DR	AH	2,722,544	U.S.	Martin	11-01-1955	
DR	AK	2,787,214	U.S.	Werner Bossard	06-25-1957	
DR	BP	4,212,981	U.S.	Yukinaga et al.	07-15-1980	
DR	BQ	4,240,820	U.S.	Dickore et al.	12-23-1980	
DR	CV	5,447,957	U.S.	Adams et al.	09-05-1985	
DR	DH	5,688,044	U.S.	Widdowson et al.	03-23-1989	
DR	DI	5,881,895	U.S.	Shiraishi et al.	04-06-1989	
DR	DL	5,865,573	U.S.	Petrie et al.	10-12-1989	
DR	DM	6,004,965	U.S.	Brau et al.	12-21-1989	
DR	DN	6,005,006	U.S.	Widdowson et al.	12-21-1989	
DR	DP	6,020,345	U.S.	Vachar et al.	02-01-2000	
DR	DR	6,040,339	U.S.	Yoshida et al.	03-21-2000	
DR	DU	6,093,742	U.S.	Salituro et al.	07-25-2000	
DR	DV	6,133,318	U.S.	Widdowson	10-17-2000	
DR	DY	6,150,415	U.S.	Hemmock et al.	11-21-2000	
DR	DZ	6,174,901 B1	U.S.	Mantlo et al.	01-16-2001	
DR	EA	6,178,389 B1	U.S.	Tekebayashi et al.	01-23-2001	
DR	EB	6,160,875 B1	U.S.	Widdowson et al.	01-30-2001	
DR	EC	6,167,799 B1	U.S.	Wood et al.	02-13-2001	
DR	ED	6,211,373 B1	U.S.	Widdowson et al.	04-03-2001	
DR	EE	6,216,539 B1	U.S.	Widdowson	04-17-2001	
DR	EF	6,242,601 B1	U.S.	Breu et al.	06-05-2001	
DR	EG	6,262,113 B1	U.S.	Widdowson et al.	07-17-2001	
DR	EH	6,271,261 B1	U.S.	Widdowson	08-07-2001	
DR	EI	6,333,341 B1	U.S.	Mantlo et al.	12-25-2001	
DR	EJ	6,338,045 B1	U.S.	Kanno et al.	01-15-2002	
DR	EK	6,344,476 B1	U.S.	Ranges et al.	02-05-2002	
DR	NW	4,548,191	U.S.	Nishiyama et al.	10-08-1985	
DR	NX	5,710,094	U.S.	Minami et al.	01-20-1996	
DR	NY	6,380,216	U.S.	Merfat et al.	04-30-2002	

Examiner  
Signature

/Deepak Rao/


Date  
Considered

06/23/2006

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	09/993,647
		Filing Date	11/27/01
		First Named Inventor	RIEDL
		Group Art Unit	1624
		Examiner Name	
Sheet 2 of 5	Attorney Docket Number	BAYER - 18A	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
DR	EM		90/02112	WO	The Nutrasweet Co.	03-08-1990		
DR	EY		96/10559	WO	Fujis WVA Pharmaceutical Co. Ltd.	04-11-1998		
DR	FD		97/17329	WO	Kirin Beer Kabushiki Kaisha	05-15-1997		
DR	FF		97/30992	WO	Bristol-Myers Squibb Co.	08-28-1997		
DR	FK		98/17267	WO	Zymogenetics, Inc.	04-30-1998		
DR	NZ		98/20868	WO	Picower Institute for Med. Res.	05-22-1998		
DR	OA		98/45268	WO	Pfizer	10-15-1998		
DR	OB		02/14311	WO	Anger	02-21-2002		
DR	OC		02/82578	WO	Boehringer Ingelheim	11-21-02		
DR	OD		0690344 A1	EP	Konica Corp.	01-03-1996		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
DR	FZ		99/32437	WO	Sloveko-Farme A.S.	07-01-1999		
DR	GG		00/43366	WO	Kirin Beer Kabushiki Kaisha	07-27-2000		
DR	GQ		0118932 A1	EP	BASF AG	08-29-1984		
DR	HD		0425443 A1	EP	CIBA-GEIGY AG	05-02-1991		
DR	HG		0202538 A1	EP	Bayer AG	11-26-1988		
DR	HH		0880433 A1	EP	Kirin Beer Kabushiki Kaisha	08-26-1998		
DR	HO		25 01 848 A1	DE	The Dow Chemical Co.	07-24-1975		
DR	HT		08-301841	JP	Green Cross Corp.	11-19-1996		
DR	HV		10-306078	JP	Mitsubishi Chemical Corp.	11-17-1998		

Examiner Signature	/Deepak Rao/	Date Considered	06/23/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	091993,647
		Filing Date	11/27/01
		First Named Inventor	RIEDL
		Group Art Unit	1624
		Examiner Name	
Sheet <u>4-3</u>	of <u>18-5</u>	Attorney Docket Number	BAYER-18A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR	IX	Abstract of EP 0405233A1, Tatsuo Sekiya et al.	
DR	JR	Grant, A.M. et al.: "Hypotensive thiadiazoles", J. Med. Chem. (1972), 15(10), pg. 1062-4.	
DR	JS	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo-3,2-a-triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 872-83	
DR	JT	Joseph T. Bryder et al., Journal of Virology, January 1987, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and induces Interleukin-8 Expression", May 17, 1996, pgs. 398-404.	
DR	JU	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), pgs. 339-350.	
DR	MP	Publication No. US 2001/0011136 A1, Publication Date: August 2, 2001, Riedl et al.	
DR	MQ	Publication No. US 2001/0018659 A1, Publication Date: August 23, 2001, Riedl et al.	
DR	MR	Publication No. US 2001/0027202 A1, Publication Date: October 4, 2001, Riedl et al.	
DR	MS	Publication No. US 2002/0185394 A1, Publication Date: November 7, 2002, Dumas et al.	
DR	MT	Publication No. US 2002/0042517 A1, Publication Date: April 11, 2002, Uday et al.	
DR	MU	Publication No. US 2001/0034447 A1, Publication Date: October 25, 2001, Riedl et al.	
DR	MV	Publication No. US 2001/0011135 A1, Publication Date: August 2, 2001, Riedl et al.	
DR	MW	Publication No. US 2002/0103253 A1, Publication Date: August 1, 2002, Ranges et al.	

Examiner Signature	/Deepak Rao/	Date Considered	06/23/2006
--------------------	--------------	-----------------	------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

06/23/2006

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/993,647
		Filing Date	11/27/01
		First Named Inventor	RIEDL B
		Group Art Unit	1624
		Examiner Name	
Sheet <del>47</del> 4 of <del>48</del> 5	Attorney Docket Number	BAYER-18A	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR	MX	Publication No. US 2001/0006975 A1, Publication Date: July 5, 2001, Wood et al.	
DR	MY	Publication No. US 2002/0062783 A1, Publication Date: May 30, 2002, Mecholdt et al.	
DR	MZ	Publication No. US 2002/0085859 A1, Publication Date: July 4, 2002, Heshimoto et al.	
DR	NA	Publication No. US 2002/0085857 A1, Publication Date: July 4, 2002, Kim et al.	
DR	N8	Publication No. US 2002/0137774 A1, Publication Date: September 26, 2002, Riedl et al.	
DR	NC	Co-pending application Serial No. 09/640,780 filed August 18, 2000.	
DR	ND	Co-pending application Serial No. 09/472,232 filed December 27, 1999.	
DR	NE	Co-pending application Serial No. 09/776,938 filed December 22, 1998.	
DR	NF	Co-pending application Serial No. 09/776,935 filed December 22, 1998.	
DR	NG	Co-pending application Serial No. 09/993,647 filed November 27, 2001.	
DR	NH	Co-pending application Serial No. 10/086,417 filed March 4, 2002.	
DR	NI	Co-pending application Serial No. 10/071,248 filed February 11, 2002.	
DR	NJ	Co-pending application Serial No. 10/308,187 filed December 3, 2002.	
DR	NK	Co-pending application Serial No. 10/381,859 filed February 11, 2003.	

Examiner Signature	/Deepak Rao/	Date Considered	06/23/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/993,647
		Filing Date	11/27/01
		First Named Inventor	RIEDL
		Group Art Unit	1624
		Examiner Name	
Sheet <del>48</del> 5 of <del>18</del> 5	Attorney Docket Number	BAYER - 18A	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DR	NL	Co-pending application Serial No. 10/361,844 filed February 11, 2003.	
DR	NM	Co-pending application Serial No. 10/361,850 filed February 11, 2003.	
DR	NN	Co-pending application Serial No. 10/060,396 filed February 1, 2002.	
DR	NO	Co-pending application Serial No. 09/458,014 filed December 10, 1999.	
DR	NP	Co-pending application Serial No. 10/125,369 filed April 19, 2002.	
DR	NQ	Co-pending application Serial No. 09/889,227 filed July 12, 2001.	
DR	NR	XP-001145518 # 4956 Patent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships, B. Riedl et al., Bayer Corporation.	
DR	NS	XP-001145779 "Antitumor Activity of a C-raf Antisense Oligonucleotide in Combination with Standard Chemotherapeutic Agents against Various Human Tumors Transplanted Subcutaneously into Nude Mice", Thomas Galgar et al., Vol. 3, 1179-1185, July 1997.	
DR	NT	XP-001145481 +2921 Phase I and Pharmacokinetic Study of the Raf Kinase Inhibitor Bay 43-9006 in Patients with Locally Advanced or Metastatic Cancer, Dirk Strumberg et al. Bayer AG.	
DR	NU	XP-002232130, "A Phase I Trial of H-ras Antisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma", C. Casey Cunningham et al., 2001 American Cancer Society, Volume 92, Number 5, pages 1265-1271.	
DR	NV	XP-002233486, MEDLINE/NLM, NLM8336809 - [Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion], Iwadata Y et al.	
DR	OE	Journal of Immunological Methods Berwick 1996, vol. 196 (2) 163-173 corresponding to DN 125-245169	

Examiner Signature	/Deepak Rao/	Date Considered	06/23/2006
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

### Complete if Known

Application Number	09/993,647
Filing Date	November 27, 2001
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1624
Examiner Name	Deepak R. RAO
Attorney Docket Number	BAYER-18A

### U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
DR	OF	3,284,433		Becker et al.	11-08-1966

### FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
DR	OG	WO	99/28305	A1	Walker	06-10-1999		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner  
Signature

/Deepak Rao/

Date  
Considered

06/23/2006

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.